Ongoing
TBVacMod
Estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. Explore different vaccine introduction scenarios based on input from country stakeholders, including national TB program and immunization program officials, on priority groups for vaccination and likely vaccine coverage. The project's key questions include: 1) who are the priority groups in different countries and what is expected level of vaccine coverage in those groups
2) how will vaccine impact differ in different introduction scenarios (vary age, priority group, coverage)
Supporting countries with prioritization of new vaccine introductions (NVI) and portfolio optimization
Support countries with using multi-criteria decision analysis (MCDA) for prioritization of new vaccine introductions (NVI) (including new TB vaccines) and portfolio optimization, embedded in the NIS development process. The project's key questions are: 1. How can we best support countries with NVI including new TB vaccine prioritization regarding access to evidence, tools, technical support? 2. What criteria do countries use when prioritizing NVIs? 3. How to best align NVI prioritization with the NIS development process.
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers
One or more new adult TB vaccines could become available in the next 5-7 years. To
assess willingness to receive a new TB vaccine, we conducted a household- and facility-based survey
among adult community members and healthcare workers (HCWs), respectively, in Lusaka, Zambia
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India
As new TB vaccines move into late-stage development, it is imperative for high-burden
countries like India to ensure timely and effective evidence-generation to inform decision-making
and accelerate vaccine development and introduction. To enable this, an in-country vaccine
mathematical modelling effort has been initiated in India.
Protecting investment in TB vaccine R&D and health systems amid debt distress and reform
IMF analysis reveals 51 countries with moderate-to-high risk of sovereign debt distress
and 9 countries in debt distress: unable to fulfill financial obligations to lenders. For many high-TB burden countries, yearly debt servicing now exceeds domestic revenue – forcing countries to cut
expenditure on health. Based on a literature review and engagement with World Bank/IMF, this
abstract presents a policy analysis of the implications of sovereign debt distress on TB vaccine
readiness and proposes debt relief and reform as innovative financial tools for creating fiscal space
for government investment in vaccine R&D and implementation
Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan
Our study assessed the willingness of pregnant women across four countries - Brazil, Ghana, Kenya, and Pakistan to receive a future TB vaccine.
Insights into TB vaccine acceptability among adolescents in Khayelitsha through community engagement
Initially designed as an internal assessment of the impact of engagement workshops, we used short surveys to understand high-school learner perspectives of vaccines, focusing on COVID 19, TB and HIV vaccines. Between 2022 and 2024, we collected responses from 350 adolescents (14-18 years old). All participants live in Khayelitsha, where high rates of TB (4224 cases notified in the last year) intersect with socio-economic challenges